ReGen Biologics to Launch Lateral CMI(TM) at 6th Biennial ISAKOS Congress

The ISAKOS congress in Florence, Italy provides the setting for
several exciting events sponsored by the European subsidiary of ReGen
Biologics (OTC: RGBI). ISAKOS is the International Society of
Arthroscopy, Knee Surgery, and Orthopaedic Sports Medicine.

During the meeting, ReGen will exhibit its flagship product, the
CMI(TM) meniscus implant, which is CE marked and cleared for sale in
Europe for both medial and lateral use. The lateral CMI has been the
subject of a post-marketing study in Europe since receiving the CE
mark in 2006 and will now be available for general sale.

ReGen is sponsoring a luncheon symposium as part of the ISAKOS
scientific program. Three topics will be discussed at this symposium.
Dr. Kenneth DeHaven of Rochester, New York will present the results of
the CMI U.S. multicenter clinical trial. Dr. Dirk Holsten of Koblenz,
Germany will review the lateral CMI surgical technique. And Dr. M.
Marcacci and Dr. S. Zaffagnini of Bologna, Italy will discuss the
preliminary clinical trial results of the lateral CMI.

"We are pleased to support the efforts of ISAKOS in presenting new
and important information, and also to offer surgeons a proven
treatment for lateral meniscus defects," said Marcel Kyburz, General
Manager of ReGen Biologics AG. "We look forward to expanding our
association with leading arthroscopic surgeons globally as we continue
to develop state of the art products."

The ISAKOS Congress provides an international forum for the
exchange of scientific information and networking with leaders in
orthopedics and sports medicine from around the world. ISAKOS is the
Society of the future providing high quality educational programs for
its members and the orthopaedic and sports medicine global community.
For more information on the society or the congress please visit
www.isakos.com.

About ReGen Biologics, Inc.:

ReGen Biologics is an orthopedic products company that develops,
manufactures and markets innovative tissue growth and repair products
for U.S. and global markets. ReGen's patented collagen scaffold
technology includes applications in orthopedics, general surgery,
spine, cardiovascular and drug delivery. ReGen's first approved
product using its collagen scaffold technology is the CMI(TM), a
meniscus application, which is cleared for sale in Europe and marketed
through ReGen's European subsidiary, ReGen Biologics AG. ReGen has
submitted a 510(k) to the FDA in the U.S. for clearance of the CMI.

ReGen is headquartered in Franklin Lakes, NJ and manufactures its
collagen scaffold products in its ISO Certified facility located in
Redwood City, CA. For more information on ReGen, visit
www.regenbio.com .

This press release contains forward-looking statements within the
meaning of the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. Such statements are based on the
current expectations and beliefs of the management of ReGen and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including those discussed in the Risk
Factors section of ReGen's 2006 annual report on Form 10-K and
additional filings with the SEC. ReGen's filings with the SEC are
available to the public at the Company's website at
http://www.regenbio.com, from commercial document-retrieval services
and at the Web site maintained by the SEC at http://www.sec.gov .